The Group Room, Radio Cancer Support Program, Expands

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 9
Volume 6
Issue 9

LOS ANGELES-The Group Room, syndicated radio’s first call-in cancer support program, has added two new stations: San Diego’s KSDO AM 1130 and Dallas/Ft. Worth’s Talk 1190 AM (KOOO), Premiere Radio Networks, Inc. has announced.

LOS ANGELES—The Group Room, syndicated radio’s first call-in cancer support program, has added two new stations: San Diego’s KSDO AM 1130 and Dallas/Ft. Worth’s Talk 1190 AM (KOOO), Premiere Radio Networks, Inc. has announced.

The program, a collaborative effort between Vital Options TeleSupport Cancer Network and Premiere, is North America’s only radio talk show for people with cancer, their families, friends, physicians, and other health care professionals.

Vital Options is a nonprofit corporation founded in 1984 by Selma Schimmel, which has evolved into the nations’ first psychosocial cancer communications organization.

The show, hosted by Ms. Schimmel, has been in production since 1996, and is sponsored by Bristol-Myers Squibb Co. and Ortho Biotech Inc. It provides direct interaction between in-studio participants and telephone callers. The show is also on the Internet live (Sundays, 4 PM EST) at http://www.premrad.com.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.